Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have earned a consensus recommendation of “Buy” from the nineteen analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seventeen have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $68.25.
A number of equities research analysts have recently issued reports on the stock. BMO Capital Markets boosted their price target on shares of Neurocrine Biosciences from $75.00 to $84.00 and gave the company an “outperform” rating in a research note on Friday, August 4th. Barclays PLC boosted their price target on shares of Neurocrine Biosciences from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Tuesday, May 2nd. ValuEngine raised shares of Neurocrine Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. BidaskClub raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $62.00 price target on shares of Neurocrine Biosciences in a research note on Monday, April 17th.
TRADEMARK VIOLATION WARNING: “Brokerages Set Neurocrine Biosciences, Inc. (NBIX) Target Price at $67.87” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://stocknewstimes.com/2017/08/11/neurocrine-biosciences-inc-nbix-given-consensus-recommendation-of-buy-by-brokerages-updated-updated.html.
In other news, insider Christopher Flint Obrien sold 8,734 shares of the company’s stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $50.00, for a total value of $436,700.00. Following the completion of the transaction, the insider now owns 57,707 shares in the company, valued at approximately $2,885,350. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Haig P. Bozigian sold 22,500 shares of the company’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $50.00, for a total transaction of $1,125,000.00. Following the completion of the transaction, the insider now owns 154,601 shares of the company’s stock, valued at approximately $7,730,050. The disclosure for this sale can be found here. Over the last three months, insiders sold 51,194 shares of company stock worth $2,629,755. Insiders own 4.80% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. bought a new position in shares of Neurocrine Biosciences during the fourth quarter valued at about $1,025,000. Dimensional Fund Advisors LP boosted its position in shares of Neurocrine Biosciences by 2.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 165,953 shares of the company’s stock valued at $6,422,000 after buying an additional 4,428 shares during the last quarter. Norges Bank acquired a new stake in shares of Neurocrine Biosciences during the fourth quarter worth $34,777,000. Teachers Advisors LLC boosted its stake in shares of Neurocrine Biosciences by 6.3% in the fourth quarter. Teachers Advisors LLC now owns 78,287 shares of the company’s stock worth $3,030,000 after buying an additional 4,668 shares in the last quarter. Finally, Opus Point Partners Management LLC boosted its stake in shares of Neurocrine Biosciences by 50.9% in the fourth quarter. Opus Point Partners Management LLC now owns 6,137 shares of the company’s stock worth $238,000 after buying an additional 2,069 shares in the last quarter. Institutional investors and hedge funds own 96.48% of the company’s stock.
Neurocrine Biosciences (NASDAQ NBIX) opened at 53.85 on Monday. The stock’s 50 day moving average is $48.33 and its 200-day moving average is $46.68. The stock’s market capitalization is $4.75 billion. Neurocrine Biosciences has a 12 month low of $37.35 and a 12 month high of $55.38.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by $0.01. The firm had revenue of $6.34 million for the quarter, compared to analyst estimates of $0.61 million. During the same quarter last year, the business earned ($0.46) earnings per share. On average, equities research analysts expect that Neurocrine Biosciences will post ($2.45) earnings per share for the current year.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
